Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans

European Journal of Pharmaceutical Sciences

Volumn 43, Issue 3, 2011, Pages 89-98

  Thörn, Helena Anna ^a   Lundahl, Anna ^a   Schrickx, Johannes Antonius ^b   Dickinson, Paul Alfred ^c   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Dextromethorphan; In vitro metabolism; Pig mRNA expressison; Pig pharmacokinetics; Testosterone; Verapamil

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; DRUG METABOLIZING ENZYME; KETOCONAZOLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; TESTOSTERONE; VERAPAMIL;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG METABOLISM; EXPERIMENTAL PIG; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE; LIVER; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; DEXTROMETHORPHAN; DICLOFENAC; GENE EXPRESSION; GLUCURONOSYLTRANSFERASE; HUMANS; JEJUNUM; KETOCONAZOLE; LIVER; MALE; MICROSOMES, LIVER; RNA, MESSENGER; SPECIES SPECIFICITY; SWINE; TESTOSTERONE; VERAPAMIL;

EID: 79956357485     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2011.03.008     Document Type: Article

References (48)

1. Achour, B., Rostami-Hodjegan, A., Barber, J., 2010. Assessing abundance of cytochrome P450 enzymes using mass spectrometry based methods: analysis of porcine liver. In: Drug Metabolism Discussion Group Meeting, Canterbury, UK.
2. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R., 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420.
3. Anzenbacher, P., Soucek, P., Anzenbacherova, E., Gut, I., Hruby, K., Svoboda, Z., Kvetina, J., 1998. Presence and activity of cytochrome P450 isoforms in minipig liver microsomes. Comparison with human liver samples. Drug Metab. Dispos. 26, 56-59.
4. Benet, L.Z., Amidon, G.L., Barends, D.M., Lennernas, H., Polli, J.E., Shah, V.P., Stavchansky, S.A., Yu, L.X., 2008. The use of BDDCS in classifying the permeability of marketed drugs. Pharm. Res. 25, 483-488.
5. Bergman, E., Hedeland, M., Bondesson, U., Lennernas, H., 2010. The effect of acute administration of rifampicin and imatinib on the enterohepatic transport of rosuvastatin in vivo. Xenobiotica 40, 558-568.
6. Bergman, E., Lundahl, A., Fridblom, P., Hedeland, M., Bondesson, U., Knutson, L., Lennernas, H., 2009. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab. Dispos. 37, 2349-2358.
7. Bogaards, J.J., Bertrand, M., Jackson, P., Oudshoorn, M.J., Weaver, R.J., van Bladeren, P.J., Walther, B., 2000. Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30, 1131-1152. (Pubitemid 32368013)
8. Custodio, J.M., Wu, C.Y., Benet, L.Z., 2008. Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv. Drug Deliv. Rev. 60, 717-733.
9. Eichelbaum, M., Mikus, G., Vogelgesang, B., 1984. Pharmacokinetics of (+)-, (-)- and (+/-)-verapamil after intravenous administration. Br. J. Clin. Pharmacol. 17, 453-458.
10. Elowsson, P., Carlsten, J., 1997. Body composition of the 12-week-old pig studied by dissection. Lab. Anim. Sci. 47, 200-202.
11. Engman, H., Tannergren, C., Artursson, P., Lennernas, H., 2003. Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. Eur. J. Pharm. Sci. 19, 57-65.
12. Gross, A.S., Heuer, B., Eichelbaum, M., 1988. Stereoselective protein binding of verapamil enantiomers. Biochem. Pharmacol. 37, 4623-4627.
13. Guengerich, F.P., 2003. Cytochromes P450, drugs, and diseases. Mol. Interv. 3, 194-204.
14. Hannon, J.P., Bossone, C.A., Wade, C.E., 1990. Normal physiological values for conscious pigs used in biomedical research. Lab. Anim. Sci. 40, 293-298.
15. Hedeland, M., Fredriksson, E., Lennernas, H., Bondesson, U., 2004. Simultaneous quantification of the enantiomers of verapamil and its N-demethylated metabolite in human plasma using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 804, 303-311. (Pubitemid 38481705)
16. Ito, K., Houston, J.B., 2005. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm. Res. 22, 103-112.
17. Jurima-Romet, M., Casley, W.L., Leblanc, C.A., Nowakowska, M., 2000. Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver. Toxicol. In Vitro 14, 253-263. (Pubitemid 30235123)
18. Kaphalia, L., Kaphalia, B.S., Kumar, S., Kanz, M.F., Treinen-Moslen, M., (2006). Efficient high performance liquid chromatograph/ultraviolet method for determination of diclofenac and 4'-hydroxydiclofenac in rat serum. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 830, 231-237.
19. Kararli, T.T., 1995. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm. Drug Dispos. 16, 351-380.
20. Kroemer, H.K., Echizen, H., Heidemann, H., Eichelbaum, M., 1992. Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects. J. Pharmacol. Exp. Ther. 260, 1052-1057.
21. Kroemer, H.K., Gautier, J.C., Beaune, P., Henderson, C., Wolf, C.R., Eichelbaum, M., 1993. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol. 348, 332-337.
22. Lennernas, H., 2007. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica 37, 1015-1051. (Pubitemid 350035536)
23. Lewis, D.F., 2003. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr. Med. Chem. 10, 1955-1972.
24. Lundahl, A., Hedeland, M., Bondesson, U., Lennernas, H., 2011. In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition and metabolism of the 5-alpha reductase inhibitor finasteride and the effects of co-administered ketoconazole. Drug Metab. Dispos., in press, doi:10.1124/dmd.110.035311.
25. Matsson, E.M., Palm, J.E., Eriksson, U.G., Bottner, P., Lundahl, A., Knutson, L., Lennernas, H., 2011. Effects of ketoconazole on the in vivo biotransformation and hepatobiliary transport of the thrombin inhibitor AZD0837 in pigs. Drug Metab. Dispos. 39, 239-246.
26. Nebbia, C., Dacasto, M., Rossetto Giaccherino, A., Giuliano Albo, A., Carletti, M., 2003. Comparative expression of liver cytochrome P450-dependent monooxygenases in the horse and in other agricultural and laboratory species. Vet. J. 165, 53-64. (Pubitemid 38001823)
27. Nelson, W.L., Olsen, L.D., Beitner, D.B., Pallow Jr., R.J., 1988. Regiochemistry and substrate stereoselectivity of O-demethylation of verapamil in the presence of the microsomal fraction from rat and human liver. Drug Metab. Dispos. 16, 184-188.
28. Nordgren, A., Karlsson, T., Wiklund, L., 2002. Glutamine concentration and tissue exchange with intravenously administered alpha-ketoglutaric acid and ammonium: a dose-response study in the pig. Nutrition 18, 496-504. (Pubitemid 34586805)
29. Paine, M.F., Hart, H.L., Ludington, S.S., Haining, R.L., Rettie, A.E., Zeldin, D.C., 2006. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos. 34, 880-886.
30. Persson, E.M., Nordgren, A., Forsell, P., Knutson, L., Ohgren, C., Forssen, S., Lennernas, H., Abrahamsson, B., 2008. Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. Eur. J. Pharm. Sci. 34, 22-29.
31. Petri, N., Bergman, E., Forsell, P., Hedeland, M., Bondesson, U., Knutson, L., Lennernas, H., 2006. First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. Drug Metab. Dispos. 34, 1182-1189.
32. Robinson, M.A., Mehvar, R., 1996. Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding. Biopharm. Drug Dispos. 17, 577-587.
33. Sandstrom, R., Karlsson, A., Knutson, L., Lennernas, H., 1998. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 15, 856-862.
34. Sandstrom, R., Knutson, T.W., Knutson, L., Jansson, B., Lennernas, H., 1999. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br. J. Clin. Pharmacol. 48, 180-189.
35. Sjodin, E., Fritsch, H., Eriksson, U.G., Logren, U., Nordgren, A., Forsell, P., Knutson, L., Lennernas, H., 2008. Intestinal and hepatobiliary transport of ximelagatran and its metabolites in pigs. Drug Metab. Dispos. 36, 1519-1528.
36. Sjogren, E., Lennernas, H., Andersson, T.B., Grasjo, J., Bredberg, U., 2009. The multiple depletion curves method provides accurate estimates of intrinsic clearance (CLint), maximum velocity of the metabolic reaction (Vmax), and Michaelis constant (Km): accuracy and robustness evaluated through experimental data and Monte Carlo simulations. Drug Metab. Dispos. 37, 47-58.
37. Skaanild, M.T., Friis, C., 1999. Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacol. Toxicol. 85, 174-180.
38. Skaanild, M.T., Friis, C., 2002. Is cytochrome P450 CYP2D activity present in pig liver? Pharmacol. Toxicol. 91, 198-203. (Pubitemid 35221364)
39. Tannergren, C., Engman, H., Knutson, L., Hedeland, M., Bondesson, U., Lennernas, H., 2004. St. John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin. Pharmacol. Ther. 75, 298-309.
40. Thorn, H.A., Hedeland, M., Bondesson, U., Knutson, L., Yasin, M., Dickinson, P., Lennernas, H., 2009. Different effects of ketoconazole on the stereoselective first-pass metabolism of R/S-verapamil in the intestine and the liver: important for the mechanistic understanding of first-pass drug-drug interactions. Drug Metab. Dispos. 37, 2186-2196.
41. Tracy, T.S., Korzekwa, K.R., Gonzalez, F.J., Wainer, I.W., 1999. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br. J. Clin. Pharmacol. 47, 545-552.
42. Tucker, G.T., Houston, J.B., Huang, S.M., 2001a. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm. Res. 18, 1071-1080.
43. Tucker, G.T., Houston, J.B., Huang, S.M., 2001b. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br. J. Clin. Pharmacol. 52, 107-117.
44. Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., Speleman, F., 2002. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3, RESEARCH0034.
45. Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., Sugiyama, Y., 2009. Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans. J. Pharmacol. Exp. Ther. 328, 652-662.
46. Winiwarter, S., Bonham, N.M., Ax, F., Hallberg, A., Lennernas, H., Karlen, A., 1998. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41, 4939-4949.
47. Vogelgesang, B., Echizen, H., Schmidt, E., Eichelbaum, M., 1984. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br. J. Clin. Pharmacol. 18, 733-740.
48. Yamazaki, H., Shimada, T., 1997. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 346, 161-169.